Ignite Creation Date:
2025-12-24 @ 6:44 PM
Ignite Modification Date:
2025-12-28 @ 1:42 PM
Study NCT ID:
NCT00522457
Status:
TERMINATED
Last Update Posted:
2011-04-29
First Post:
2007-08-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
Sponsor:
Neovii Biotech
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-01
Start Date Type:
None
Primary Completion Date:
2009-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2009-12
Completion Date Type:
ACTUAL
First Submit Date:
2007-08-28
First Submit QC Date:
None
Study First Post Date:
2007-08-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2011-03-01
Results First Submit QC Date:
None
Results First Post Date:
2011-04-29
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2011-04-28
Last Update Post Date:
2011-04-29
Last Update Post Date Type:
ESTIMATED